 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...27282930313233343536373839» |
- MRTX849 / Mirati, AMG 510 / Amgen
The Emerging Anti-Cancer Target KRAS G12C: A Pangenomic Study (LACC West Exhibit Hall A, Poster Board Number: 279) - Jan 24, 2020 - Abstract #USCAP2020USCAP_2196;
KRAS G12C GA have different cancer type associations, GAs and biomarkers predicting responsiveness to non-KRAS targeted therapies and ICPI treatments. Given the recent successes of two anti KRAS G12C drugs in early clinical trials (Amgen AMG510; Miratti MRTX849), further study of the distribution, co-mutations potentially impacting drug response and potential for combination trials with ICPI in KRAS G12C altered malignancies appears warranted.
- || AMG 510 / Amgen
Practical Fragments: Fragments in the clinic: AMG 510 #KRAS https://t.co/ibBWjvLOmD (Twitter) - Jan 20, 2020
- |||| AMG 510 / Amgen
We will be opening the AMG-510+/-MEK⛔️ or PD-L1⛔️ for the KRAS-G12C🧬. #CRCSM February 2020. #PrecisionMedicine (Twitter) - Dec 28, 2019
- ||||| AMG 510 / Amgen
PD(L)-1 Biomarker, IO Biomarker: The targetable KRAS G12C mutation... AMG 510 AMG510 + PDL1 or MEK(i) Mirati Eli Lili trial But also on lookout for other KRAS appoaches: MODERNA vaccine Boerhinger PAN-KRAS agent. (Twitter) - Dec 28, 2019
- || Lumakras (sotorasib) / Amgen
Trial completion date, Combination therapy, Monotherapy, Metastases: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov) - Dec 23, 2019
P1/2, N=350, Recruiting, Sponsor: Amgen
Given the recent successes of two anti KRAS G12C drugs in early clinical trials (Amgen AMG510; Miratti MRTX849), further study of the distribution, co-mutations potentially impacting drug response and potential for combination trials with ICPI in KRAS G12C altered malignancies appears warranted. Trial completion date: Apr 2023 --> Apr 2024
- ||| Lumakras (sotorasib) / Amgen
Enrollment open, Trial completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Dec 23, 2019
P1b, N=120, Recruiting, Sponsor: Amgen
Trial completion date: Apr 2023 --> Apr 2024 Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Dec 2024
- ||| AMG 510 / Amgen
Testing for KRAS and NRAS may not have a targeted drug (yet, AMG510 is changing that), but those mutations when present are a contraindication for EGFR inhibitors because worsen outcomes and expensive drugs .:. Makes sense given their predictive value (Twitter) - Dec 19, 2019
- ||| AMG 510 / Amgen
Clinical: Interesting information to define sequentiality in KRAS + subjects in light of the data of AMG510 and others. Interesting to see the grouped data of 042+189 (Twitter) - Dec 12, 2019
- ||||| Keytruda (pembrolizumab) / Merck (MSD), AMG 510 / Amgen
Clinical: Further study is obviously needed. Ongoing efforts are looking at AMG510+pembro in G12C patients. Can we use KRAS as a surrogate for PDL1 and TMB? Should we avoid pembro alone in KRAS WT? #lcsm @myESMO @SylvesterCancer @JackWestMD @n8pennell @oncoalert @weoncologists (Twitter) - Dec 12, 2019
- |||| AMG 510 / Amgen
Video: AMG-510 hits the @NIH https://t.co/NPZKszQ8CO website! https://t.co/qmUBtd2ZvU 3 videos w/ Dr. Fakih of @cityofhope @myESMO "strong signal re stability" & no dose limiting toxicities @OBRtweets https://t.co/9oCJzdE9ru https://t.co/Mtjw3Pv7Px @JVOncology https://t.co/xcsEciVI0c (Twitter) - Dec 10, 2019
- ||| AMG 510 / Amgen
P2 data: Keep an eye on @Amgen pipeline drug, AMG 510, which has shown to induce regression in mice bearing KRASG12C mutated tumors. Phase II studies underway. #oncopharm #kras (Twitter) - Dec 6, 2019
- || zotatifin (eFT226) / eFFECTOR Therap
Enrollment open: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (clinicaltrials.gov) - Dec 5, 2019
P1/2, N=45, Recruiting, Sponsor: Effector Therapeutics
Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Dec 2024 Not yet recruiting --> Recruiting
- ||| Lumakras (sotorasib) / Amgen
New P1 trial, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Dec 3, 2019
P1b, N=120, Not yet recruiting, Sponsor: Amgen
- ||| Lumakras (sotorasib) / Amgen
Enrollment change, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov) - Dec 1, 2019
P1/2, N=350, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting N=158 --> 350 | Trial primary completion date: Dec 2022 --> Apr 2023
- |||| AMG 510 / Amgen
Dr. shokat highlights contrast between time from mutated oncogene discovery and drug approval; compares KRAS and BRAF #SNO2019 speaks about his elegant preclinical work targeting KRAS G12C, reviews different agents in clinical development and recent results with AMG510 compound (Twitter) - Nov 23, 2019
- |||| AMG 510 / Amgen
Clinical: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature https://t.co/MM8HIOK0wh (Twitter) - Nov 13, 2019
- || AMG 510 / Amgen
Carmot and Amgen tested around 100000 molecules before chosing AMG510.... unbelievable (Twitter) - Nov 5, 2019
- ||||| AMG 510 / Amgen
Fast track designation: FDA Grants AMG 510 Fast Track Designation for KRAS G12C+ NSCLC https://t.co/fxMID3KYJZ via @TargetedOnc @DavidHongMD @Amgen (Twitter) - Nov 4, 2019
- |||||| MRTX849 / Mirati, AMG 510 / Amgen
Clinical: Interesting that this G12C inhibitor MRTX849 reported here as active in colon cancer based on 1/4 responses. Data @ESMO19 showed AMG510 in only 1/25 G12C-mutated colon cases? Investigational KRAS G12C Inhibitor for KRAS-Mutant Solid Tumors - The ASCO Post https://t.co/JiK9uDg3Ki (Twitter) - Nov 4, 2019
- | AMG 510 / Amgen
But $BGNE's 50% commercial share of AMG-510 for 7 yrs offsets a lot of that $1.25B. (Twitter) - Oct 31, 2019
- ||||| AMG 510 / Amgen
Monotherapy: Interesting that AMG 510 is synergistic with MEK inhibitors and immunotherapy, so monotherapy trials may only be the beginning for KRAS G12C #LCSM (Twitter) - Oct 31, 2019
- |||| AMG 510 / Amgen
Clinical, Next-Generation Sequencing: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature @SarahCannonDocs @BandVsCancer #NGS https://t.co/KvvmXOXkJr (Twitter) - Oct 31, 2019
- |||| MRTX849 / Mirati, AMG 510 / Amgen
Major milestone in #KRAS #PrecisionMedicine 👉Back to back papers @nature & @CD_AACR .The #KRASG12C Inhibitors #AMG510 & #MRTX849 in KRAS +#cancer https://t.co/gu2faqGpBk & https://t.co/pmp2wHQnSk (Twitter) - Oct 30, 2019
- ||| MRTX849 / Mirati, AMG 510 / Amgen
Major milestone in #KRAS #PrecisionMedicine 👉Back to back papers @nature & @CD_AACR .The #KRASG12C Inhibitors #AMG510 & #MRTX849 in KRAS +#cancer https://t.co/gu2faqGpBk & https://t.co/pmp2wHQnSk (Twitter) - Oct 30, 2019
- ||||| AMG 510 / Amgen
Clinical: Undruggable #KRAS is now druggable x 2 👉The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity @nature @Amgen @DavidHongMD https://t.co/pmp2wHQnSk (Twitter) - Oct 30, 2019
- | MRTX849 / Mirati, AMG 510 / Amgen
besides, the bioavailability of mrtx849 is poor, because of a lower Cmax and AUC (compared to AMG510) (Twitter) - Oct 28, 2019
- |||| AMG 510 / Amgen
Clinical: Happy to have other entrants in the race, along with AMG 510. Can't wait to have one or both of these broadly available to patients with NSCLC that harbors a KRAS G12C mutation. (Twitter) - Oct 28, 2019
- ||||| AMG 510 / Amgen
Clinical, PK/PD data: Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors - @mgfakih et al. #ASCO19 Abstract 3003 https://t.co/l8cX18pagO #NCT03600883 #caxtx @AmgenOncology (Twitter) - Oct 23, 2019
P1/2
- ||||| AMG 510 / Amgen
Clinical: Bob Li reporting early results of KRAS G12C inhibitor AMG 510. 34 #lungcancer patients, promising responses, well tolerated #NACLC19 #LCSM #OncoAlert (Twitter) - Oct 11, 2019
- ||||| AMG 510 / Amgen
Clinical, PK/PD data: Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors - @mgfakih et al. #ASCO19 Abstract 3003 https://t.co/l8cX18pagO #NCT03600883 #caxtx @AmgenOncology (Twitter) - Oct 11, 2019
P1/2
- AMG 510 / Amgen
Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer (Imperial Ballroom (B2 Level)) - Oct 10, 2019 - Abstract #IASLCNACLC2019IASLC_NACLC_184;
P1/2
AMG 510 is well tolerated at all 4 dose levels and shows antitumor activity when administered as monotherapy to patients with advanced KRASG12C mutant NSCLC. Enrollment is ongoing (ClinicalTrials.gov identifier, NCT03600883).
- | Lumakras (sotorasib) / Amgen
Trial completion date, Combination therapy, Monotherapy, Metastases: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov) - Oct 9, 2019
P1/2, N=158, Recruiting, Sponsor: Amgen
Enrollment is ongoing (ClinicalTrials.gov identifier, NCT03600883). Trial completion date: Dec 2023 --> Mar 2023
- || AMG 510 / Amgen
Agree with @JackWestMD .. however there was a grade 5 pulmonary event reported in the AMG510 trial... too early to draw any conclusions but perhaps warrants some caution (Twitter) - Oct 8, 2019
- ||||| AMG 510 / Amgen
Clinical, PK/PD data: Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors - @mgfakih et al. #ASCO19 Abstract 3003 https://t.co/l8cX18pagO #NCT03600883 #caxtx @AmgenOncology (Twitter) - Oct 7, 2019
P1/2
- |||| AMG 510 / Amgen
Video: VIDEO: AMG510 for targeting KRAS G12C mutant solid tumors w/ @mgfakih MD of @cityofhope at #ESMO2019: https://t.co/VHaPoQnBsE #ESMO19 @myESMO @VJOncology #Cancer (Twitter) - Oct 7, 2019
- ||||| AMG 510 / Amgen
Clinical, PK/PD data: Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors - @mgfakih et al. #ASCO19 Abstract 3003 https://t.co/l8cX18pagO #NCT03600883 #caxtx @AmgenOncology (Twitter) - Oct 4, 2019
P1/2
- ||| AMG 510 / Amgen
Video: AMG510 KRASG12C nice video #ESMO19 Thank you @VJOncology Watch on youtube https://t.co/oGqnU5FSXa (Twitter) - Sep 29, 2019
- |||| AMG 510 / Amgen
AMG510 (first in class inibidor KRAS) mostrou-se ativo no Ca pulmão KRAS mutado, demanda não atendida até então Resposta em 5/10 pctes (1 ainda não avaliado) com Ca pulmão metastático refratário KRAS G12C mutado #MOCnaESMO #ESMO19 #LCSM #lungcancer @FabioSchutz78 @camillayamada (Twitter) - Sep 28, 2019
- |||| AMG 510 / Amgen
Clinical: Efficacy of AMG 510 specifically in CRC, via M Fakih #ESMO19 $AMGN $MRTX (Twitter) - Sep 28, 2019
- ||| AMG 510 / Amgen
Reminder of AMG 510 in NSCLC via T Arkenau #ESMO19 $AMGN $MRTX (Twitter) - Sep 28, 2019
- ||| AMG 510 / Amgen
AMG 510 via discussant T Arkenau #ESMO19 $AMGN $MRTX (Twitter) - Sep 28, 2019
- || AMG 510 / Amgen
I'll be live tweeting the $AMGN AMG 510 KRAS slides starting 10:45am ET Saturday #ESMO19 $MRTX (Twitter) - Sep 27, 2019
- ||| AMG 510 / Amgen
$AMGN AMG 510 KRAS abstract at #ESMO19 is placeholder only. Another day’s agony for $MRTX bulls (Twitter) - Sep 26, 2019
- AMG 510 / Amgen
Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer (Room 1) - Sep 26, 2019 - Abstract #IASLCNACLC2019IASLC_NACLC_47;
- | zotatifin (eFT226) / eFFECTOR Therap
New P1/2 trial: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (clinicaltrials.gov) - Sep 16, 2019
P1/2, N=45, Not yet recruiting, Sponsor: Effector Therapeutics
- |||| AMG 510 / Amgen
Clinical: We're screening all our #PancreaticCancer patients for KRAS G12C specifically for this trial of AMG510. The non-NSCLC and non-CRC cohort is open! #pancsm @UFHealthCancer (Twitter) - Sep 14, 2019
- Comprehensive pan-cancer analysis of KRAS genomic alterations (GA) including potentially targetable subsets (Tarragona Auditorium (Hall 7)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3359;
G12C is most common in LUAD and associated with smoking, elevated TMB and PD-L1 positivity. As multiple trials of novel therapeutic agents are currently enrolling for KRAS GA, CGP to identify these alterations is needed.
- AMG 510 / Amgen
Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours (Alicante Auditorium (Hall 3)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3165;
P1/2
Early results suggest antitumor activity of single-agent AMG 510 in pts with KRAS G12C mutant solid tumors. Updated results will be presented.
- |||| selpercatinib (LOXO-292) / Loxo Oncology, AMG 510 / Amgen
Good reminder from @VPrasadMDMPH about need for RCTs especially in light of data with targeted therapies (selpercatinib and AMG 510) presented at @IASLC #WCLC19 and many on @twitter questioning need for follow up RCTs @JackWestMD @HenryJOncology (Twitter) - Sep 10, 2019
- |||| AMG 510 / Amgen
Clinical, P2 data: This has been IMO the top 1 presentation at the recent #WCLC19 . If confirmed AMG510 will have a great impact on many patients suffering from NSCLC. Happy to humbly contribute to the KRAS story at the @Hopitaux_unige by opening the phase II. @DralexGva (Twitter) - Sep 10, 2019